Log in

NASDAQ:INSM - Insmed Stock Price, Forecast & News

$26.34
-3.51 (-11.76 %)
(As of 02/26/2020 06:19 AM ET)
Today's Range
$25.96
Now: $26.34
$29.04
50-Day Range
$19.74
MA: $26.36
$33.98
52-Week Range
$15.33
Now: $26.34
$34.94
Volume2.32 million shs
Average Volume1.55 million shs
Market Capitalization$2.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.12
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.84 million
Book Value$2.70 per share

Profitability

Net Income$-324,280,000.00
Net Margins-291.19%

Miscellaneous

Employees373
Market Cap$2.35 billion
Next Earnings DateN/A
OptionableOptionable

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.


Insmed (NASDAQ:INSM) Frequently Asked Questions

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) posted its earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.01. The biopharmaceutical company earned $45.70 million during the quarter, compared to analyst estimates of $45.06 million. Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. The company's revenue was up 366.3% compared to the same quarter last year. View Insmed's Earnings History.

What price target have analysts set for INSM?

7 brokerages have issued 1 year price objectives for Insmed's stock. Their forecasts range from $20.00 to $56.00. On average, they anticipate Insmed's share price to reach $43.43 in the next year. This suggests a possible upside of 64.9% from the stock's current price. View Analyst Price Targets for Insmed.

What is the consensus analysts' recommendation for Insmed?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.

Has Insmed been receiving favorable news coverage?

News coverage about INSM stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Insmed earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Insmed.

Are investors shorting Insmed?

Insmed saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 12,940,000 shares, a drop of 8.6% from the January 15th total of 14,150,000 shares. Based on an average daily volume of 946,400 shares, the days-to-cover ratio is presently 13.7 days. Approximately 15.3% of the company's shares are sold short. View Insmed's Current Options Chain.

Who are some of Insmed's key competitors?

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Gilead Sciences (GILD), Geron (GERN), Intercept Pharmaceuticals (ICPT), Incyte (INCY), Capstone Turbine (CPST), NVIDIA (NVDA), Alibaba Group (BABA), Bausch Health Companies (BHC) and CHIMERA INVT CO/SH NEW (CIM).

Who are Insmed's key executives?

Insmed's management team includes the folowing people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

Who are Insmed's major shareholders?

Insmed's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Janus Henderson Group PLC (13.06%), Palo Alto Investors LP (7.67%), Eagle Asset Management Inc. (1.69%), Geode Capital Management LLC (1.36%) and Fairmount Funds Management LLC (1.11%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.

Which institutional investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of America Corp DE, Point72 Asset Management L.P., Marshall Wace LLP, Palo Alto Investors LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Rafferty Asset Management LLC. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Donald J Hayden Jr, John Goll, Orlov S Nicole Schaeffer and William Lewis. View Insider Buying and Selling for Insmed.

Which institutional investors are buying Insmed stock?

INSM stock was acquired by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, FMR LLC, Goldman Sachs Group Inc., Lord Abbett & CO. LLC, AXA, California Public Employees Retirement System, Geode Capital Management LLC and Franklin Resources Inc.. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $26.34.

How big of a company is Insmed?

Insmed has a market capitalization of $2.35 billion and generates $9.84 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. Insmed employs 373 workers across the globe.View Additional Information About Insmed.

What is Insmed's official website?

The official website for Insmed is http://www.insmed.com/.

How can I contact Insmed?

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]


MarketBeat Community Rating for Insmed (NASDAQ INSM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  441 (Thanks for Voting!)
Underperform Votes:  442 (Thanks for Voting!)
Total Votes:  883
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Asset Allocation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel